EASL 2025 Research: Presentation by Michael Roden, MD

Target RWE’s MASH steering committee member Michael Roden, MD co-authored a new Target RWE study which was presented at EASL 2025 titled, “Type 2 diabetes increases the risk of progression to metabolic dysfunction-associated steatohepatitis-related cirrhosis in a real-world setting.”

In this new analysis from the TARGET-NASH cohort, researchers demonstrate that individuals with type 2 diabetes face significantly higher risk of progressing from MASH to cirrhosis, independent of age, sex, or fibrosis risk group.

This data underscores the urgent need for early MASH detection in people with T2D, especially as MASLD continues to rise globally. Watch the video presentation to learn more about the impact of diabetes on liver disease progression and why proactive screening and intervention strategies are critical to reducing the burden of MASLD-related cirrhosis in at-risk populations.